Citigroup Inc Galapagos Nv Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Galapagos Nv stock. As of the latest transaction made, Citigroup Inc holds 54,737 shares of GLPG stock, worth $1.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

54,737

Previous 127,849 57.19%

Holding current value

$1.36 Million

Previous $5.2 Million 66.1%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$32.2 - $42.44 $2.35 Million - $3.1 Million	-73,112 Reduced 57.19%	54,737 $1.76 Million
Q4 2023 Feb 09, 2024	BUY	$31.87 - $40.71 $1.18 Million - $1.51 Million	37,163 Added 40.98%	127,849 $5.2 Million
Q3 2023 Nov 09, 2023	BUY	$34.17 - $42.98 $3.06 Million - $3.84 Million	89,451 Added 7243.0%	90,686 $3.13 Million
Q2 2023 Aug 10, 2023	SELL	$37.4 - $44.52 $3,927 - $4,674	-105 Reduced 7.84%	1,235 $50,000
Q1 2023 May 11, 2023	SELL	$36.5 - $48.0 $14,344 - $18,864	-393 Reduced 22.68%	1,340 $51,000

Q4 2022 Feb 09, 2023	BUY	$37.44 - $46.51 $14,601 - $18,138	390 Added 29.04%	1,733 $76,000
Q3 2022 Nov 10, 2022	SELL	$42.27 - $57.6 $5,326 - $7,257	-126 Reduced 8.58%	1,343 $58,000
Q2 2022 Aug 10, 2022	SELL	$52.3 - $71.59 $234,356 - $320,794	-4,481 Reduced 75.31%	1,469 $82,000
Q1 2022 May 12, 2022	SELL	$51.32 - $68.5 $70,718 - $94,393	-1,378 Reduced 18.8%	5,950 $369,000
Q4 2021 Feb 10, 2022	SELL	$47.03 - $57.12 $36,636 - $44,496	-779 Reduced 9.61%	7,328 $404,000
Q3 2021 Nov 10, 2021	BUY	$52.17 - $70.2 $422,942 - $569,111	8,107 New	8,107 $426,000

Others Institutions Holding GLPG

# of Institutions

Shares Held

16.5M

Call Options Held

77.1K

Put Options Held

57.2K

View Full List

About GALAPAGOS NV

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.63B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

More about GLPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account